Cryoport, Inc. (NASDAQ:CYRX) CEO Sells $20,681.20 in Stock

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 2,980 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $6.94, for a total value of $20,681.20. Following the completion of the sale, the chief executive officer now owns 762,419 shares in the company, valued at $5,291,187.86. This trade represents a 0.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The stock was sold at an average price of $6.29, for a total value of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total value of $20,364.24.

Cryoport Price Performance

Shares of CYRX stock traded down $0.15 during trading hours on Friday, hitting $6.09. 272,866 shares of the company's stock were exchanged, compared to its average volume of 534,492. The company has a market capitalization of $303.95 million, a PE ratio of -1.80 and a beta of 1.67. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $20.11. The business's 50 day simple moving average is $6.68 and its 200-day simple moving average is $7.31.

Remove Ads

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same period in the prior year, the firm earned ($0.29) earnings per share. On average, equities research analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CYRX. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a "buy" rating and a $11.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th. Finally, UBS Group raised shares of Cryoport from a "neutral" rating to a "buy" rating and set a $10.00 price objective for the company in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, Cryoport currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

Hedge Funds Weigh In On Cryoport

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Thematics Asset Management lifted its position in Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock valued at $13,828,000 after purchasing an additional 1,087,800 shares during the last quarter. Fred Alger Management LLC raised its holdings in Cryoport by 49.9% during the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock valued at $21,887,000 after buying an additional 898,481 shares during the last quarter. Cadian Capital Management LP boosted its position in Cryoport by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock valued at $38,332,000 after buying an additional 609,021 shares during the period. Point72 Asset Management L.P. bought a new stake in Cryoport in the 3rd quarter worth $3,405,000. Finally, Millennium Management LLC increased its position in shares of Cryoport by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after acquiring an additional 409,353 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.